Retatrutide, a new dual stimulator of the GLP-1 binding site and glucose-dependent insulinotropic polypeptide (GIP) receptor , is exhibiting promising outcomes in early clinical assessments . Recent https://active-bookmarks.com/story21263357/retatrutide-emerging-studies-and-potential-clinical-applications